EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness Analysis of Xpert MTB/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis

Omar K Siddiqi iD, Beate Jahn, Ursula Rochau, Stewart Walukaga iD, Radha Rajasingham iD, Uwe Siebert iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Omar K Siddiqi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Neurology Program, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Tuberculosis, Meningeal, Cost-Benefit Analysis, HIV Infections, Mycobacterium tuberculosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human immunodeficiency virus (HIV-1)–associated tuberculous meningitis (TBM) is the most lethal form of extrapulmonary tuberculosis, with a high mortality rate in sub-Saharan Africa. Due to the limited diagnostic performance of current testing, empiric treatment is frequently required as untreated TBM is almost universally fatal. Xpert MTB/RIF Ultra (Xpert Ultra) is the World Health Organization recommended first-line diagnostic test for TBM but is costly relative to the standard of care (SOC). We performed a cost-effectiveness analysis of Xpert Ultra for HIV-associated TBM in Zambia.

Methods

We developed a decision-analytic model comparing a diagnostic strategy guided by CSF Xpert Ultra plus the SOC (cerebrospinal fluid biochemistry and clinical suspicion) versus the SOC alone in adults with HIV and suspected TBM. Costs were calculated from a healthcare perspective, including medication, supplies, personnel, and overhead. The primary outcome was the incremental cost-effectiveness ratio in US dollars per quality-adjusted life-year gained. Sensitivity analyses and cost-effectiveness acceptability curves assessed robustness across a range of willingness-to-pay thresholds.

Results

Xpert Ultra plus the SOC was cost-effective, yielding an incremental cost-effectiveness ratio of $242.76 per quality-adjusted life-year gained. The number needed to test to prevent 1 TBM death was 125. Sensitivity analyses showed that cost-effectiveness was most influenced by TBM prevalence, the TBM mortality rate in treated patients, and the probability of empiric treatment. Xpert Ultra was approximately 88% likely to be cost-effective across a broad willingness-to-pay range.

Conclusions

Xpert Ultra is cost-effective for diagnosing HIV-associated TBM in Zambia. These findings support World Health Organization guidelines recommending Xpert Ultra in high-burden, resource-limited settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, MeningealCost-Benefit AnalysisHIV InfectionsMycobacterium tuberculosisMolecular Diagnostic TechniquesHumansCost-Effectiveness AnalysisZambiaAdultRapid Diagnostic Tests

Stichwörter der Autor:innen

HIVXpert UltraZambiacost-effectiveness analysistuberculous meningitis

Autor:innen und Institutionen

  • Global Neurology Program, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Center for Vaccines and Virology Research, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Department of Internal Medicine, University of Zambia School of Medicine, Lusaka, Zambia.
  • Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL-University for Health Sciences and…
  • RAND Graduate School, RAND, Santa Monica, California, USA.
  • Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota Medical Center,Minneapolis, Minnesota, USA.

ORCID-Profile: Omar K Siddiqi, Stewart Walukaga, Radha Rajasingham, Uwe Siebert

Förderung

  • NINDS NIH HHS
  • NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Institutes of Health

Zitieren

APA

Siddiqi, O. K., Jahn, B., Rochau, U., Walukaga, S., Rajasingham, R., & Siebert, U. (2026). Cost-Effectiveness Analysis of Xpert MTB/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag348

Vancouver

Siddiqi OK, Jahn B, Rochau U, Walukaga S, Rajasingham R, Siebert U. Cost-Effectiveness Analysis of Xpert MTB/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag348

BibTeX
@article{Siddiqi2026,
  author = {Siddiqi, Omar K and Jahn, Beate and Rochau, Ursula and Walukaga, Stewart and Rajasingham, Radha and Siebert, Uwe},
  title = {Cost-Effectiveness Analysis of Xpert MTB/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag348}
}
Kostenlos starten →